Semnur Pharmaceuticals, Inc. (SMNR): Cash & Equivalents

Annual figures by period end, from SEC filings.

$20.0K
As of 2025-12-31
$39.0K
As of 2026-06-30
-71.0%
3-year compound annual growth
$819.7K2022-12-31: $819.7K2023-12-31: $204.5K2024-12-31: $12.0K2025-12-31: $20.0K$20.0K
2022-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$20.0K+66.7%2026-02-27, Balance as of period end
2024-12-31$12.0K-94.1%2026-02-27, Balance as of period end
2023-12-31$204.5K-75.1%2024-04-01, Balance as of period end
2022-12-31$819.7Kn/a2024-04-01, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Semnur Pharmaceuticals, Inc. (SMNR)2025-12-31$20.0K+66.7%
NeuroSense Therapeutics Ltd. (NRSN)2025-12-31$166.0K-95.1%
Alzamend Neuro, Inc. (ALZN)2026-04-30$710.7K-82.0%
Inhibitor Therapeutics, Inc. (INTI)2025-12-31$2.38M-57.6%
Vaccinex, Inc. (VCNX)2024-12-31$1.11M-27.9%
Provectus Biopharmaceuticals, Inc. (PVCT)2025-12-31$251.3K-18.3%
Lipella Pharmaceuticals Inc. (LIPO)2024-12-31$2.18M-33.7%
Artelo Biosciences, Inc. (ARTL)2025-12-31$600.0Kn/a
BullFrog AI Holdings, Inc. (BFRG)2025-12-31$2.18M-59.8%

Compare SMNR, NRSN, ALZN, INTI side by side · Screen every company in Pharmaceutical Preparations ↗